DNMT1 and primary cutaneous T-cell non-Hodgkin lymphoma: The DNMT inhibitors 5-Aza (azacytidine; Vidaza) and 5-Aza-20-deoxycytidine (decitabine; Dacron) have received FDA approval for the treatment of cutaneous T-cell lymphoma and bone marrow cancer, respectively [2, 220].